Search - tctmd.com

Displaying 61 - 80 of 129

Sort: Relevancy | Date

Presentation TCT 2019

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Presenter: Ian Meredith AM

September 26, 2019

Presentation TCT 2019

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Presenter: Elazer Edelman

September 26, 2019

Presentation TCT 2019

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

Presenter: Krishna Rocha-Singh

September 26, 2019

Presentation TCT 2019

New Insights From Our Meta-Analysis of Paclitaxel-Coated Device Randomized Trials for SFA Disease (And the Response It Has Generated)

Presenter: Konstantinos Katsanos

September 26, 2019

Presentation TCT 2019

1-Year Late Lumen Loss With a Polymer-Coated Paclitaxel-Eluting Stent and a Polymer-Free Paclitaxel-Coated Stent for Femoropopliteal Disease: Study Results

Presenter: Daizo Kawasaki

September 26, 2019

Presentation TCT 2019

New Crossing Techniques for Complex Femoropopliteal Disease

Presenter: Makoto Utsunomiya

September 26, 2019

Presentation TCT 2019

Mortality Risk Following Application of Paclitaxel-Coated Devices in Femoropopliteal Lesion: Results From the CAROOT Study

Presenter: Yoshimitsu Soga

September 26, 2019

Presentation TCT 2019

TCT 63: Jetstream Atherectomy for the Treatment of In-stent Restenosis of the Femoropopliteal Artery: Preliminary Results of the JET-ISR Study

Presenter: Nicolas Shammas

September 25, 2019

Presentation TCT 2019

TCT 62: A polymer-free paclitaxel eluting stent (Zilver® PTX®) versus a bare metal stent (Misago®) for de novo femoropopliteal lesions (BATTLE): a randomised trial

Presenter: Yann Gouëffic

September 25, 2019

Presentation TCT 2019

Can Baseline IVUS Predict Dissection Patterns of Femoropopliteal Lesions?

Presenter: Daizo Kawasaki

September 25, 2019

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Shelley Wood

September 19, 2019

News Daily News

AHA Outlines Diagnosis, Treatment Options for Underrecognized Critical Limb Ischemia

Caitlin E. Cox

August 12, 2019

News Daily News

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

Todd Neale

August 07, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Daily News

US Data Convey the Scope of Bleeding in Lower-Extremity Peripheral Interventions

Caitlin E. Cox

June 18, 2019

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Conference News SCAI 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Yael L. Maxwell

May 21, 2019

News Features

Peripheral Vision: As Office-Based Practices Proliferate, Who Is Watching Out for Patients?

Caitlin E. Cox

May 01, 2019

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

Advertisement

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

New Insights From Our Meta-Analysis of Paclitaxel-Coated Device Randomized Trials for SFA Disease (And the Response It Has Generated)

1-Year Late Lumen Loss With a Polymer-Coated Paclitaxel-Eluting Stent and a Polymer-Free Paclitaxel-Coated Stent for Femoropopliteal Disease: Study Results

New Crossing Techniques for Complex Femoropopliteal Disease

Mortality Risk Following Application of Paclitaxel-Coated Devices in Femoropopliteal Lesion: Results From the CAROOT Study

TCT 63: Jetstream Atherectomy for the Treatment of In-stent Restenosis of the Femoropopliteal Artery: Preliminary Results of the JET-ISR Study

TCT 62: A polymer-free paclitaxel eluting stent (Zilver® PTX®) versus a bare metal stent (Misago®) for de novo femoropopliteal lesions (BATTLE): a randomised trial

Can Baseline IVUS Predict Dissection Patterns of Femoropopliteal Lesions?

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

AHA Outlines Diagnosis, Treatment Options for Underrecognized Critical Limb Ischemia

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

US Data Convey the Scope of Bleeding in Lower-Extremity Peripheral Interventions

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Peripheral Vision: As Office-Based Practices Proliferate, Who Is Watching Out for Patients?

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content